TwitPic public timeline (Free subscription) | 04/01/2009
Copy & paste this HTML into your webpage 
Remember! Twitpic Community Guidelines specify that if you post a Twitpic photo on an external website, the photo must link back to its photo page.
The Street (Free subscription) | 16/12/2008
A chartist's ability to predict a stock's movements can be uncanny.
Xconomy (Free subscription) | 15/12/2008
Venture and private equity firms apparently have clamped down on much of their funding activities in San Diego, but some local firms were able to take advantage of state and federal sources of cash last week. We also saw the Food and Drug Administration give Amylin a break and Qualcomm’s top executives offer their outlook [...]
Fool.com (Free subscription) | 12/12/2008
Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
San Diego Union (Free subscription) | 12/12/2008
Shares of Amylin Pharmaceuticals jumped as much as 30 percent yesterday after the San Diego company and its partners said they would seek approval for their long-acting version of the diabetes treatment Byetta by the middle of next year.
Xconomy (Free subscription) | 11/12/2008
Amylin Pharmaceuticals stock shot up this morning after the company said it had some good fortune in dealings with the FDA. The San Diego biotech said it will be able file an application to market its diabetes drug, the once-weekly version of exenatide, in the first half of 2009 after all. That’s despite a warning [...]
Medical News Today (Free subscription) | 10/12/2008
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of BYETTA(R) (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.
Fool.com (Free subscription) | 09/12/2008
Drug companies will have to wait for important decision on diabetes drug.
Indy Star (Free subscription) | 09/12/2008
Indianapolis Amylin Pharmaceuticals and Eli Lilly and Co. say the U.S. Food and Drug Administration is continuing to review their request to market the popular diabetes drug Byetta as standalone therapy in type 2 diabetics with blood-sugar control problems, according to a news release. The review might extend into 2009. (Star report)
Fiercebiotech (Free subscription) | 05/12/2008
Fearing competition from generic biotech drugs , Amgen shelled out $2.4 million last quarter lobbying the federal government. Amylin Pharmaceuticals also spent $540K on the same issue. While a system to approve generic pharmaceuticals has long been in place, no such pathway exists for quickly approving generic biotech drugs. This has been a major boon for biotech companies since they don't have to...
www.OSIR.org.in (Free subscription) | 30/11/2008
Nov 4 (Reuters) - Genzyme Corp (GENZ.O: Quote , Profile , Research , Stock Buzz ) said it would co-develop and market two adult stem cell products of Osiris Therapeutics (OSIR.O: Quote , Profile , Research , Stock Buzz ) that are being tested for Source: www.reuters.com Amylin, Orient-Express, PFG, Sun: U.S. Equity Movers [...]
www.OSIR.org.in (Free subscription) | 29/11/2008
Medical device maker NuVasive Inc. maintained its 2008 profit forecast, but predicted increased revenue that was above Wall Street expectations. NuVasive (nasdaq: NUVA - news - people ) now expects revenue of $245 million to $247 million, up from its Source: www.forbes.com Amylin, Orient-Express, PFG, Sun: U.S. Equity Movers (Correct) - BloombergNov. 4 (Bloomberg) [...]
Acidity Info (Free subscription) | 29/11/2008
The calculated guess of the costs of diabetes diligence bordered via Europe amount to 42.8 million International Dollars per year.(9) About Lilly and Amylin Through a long-standing commitment to diabetes care, Lilly bestow patients subsequent to breakthrough nurture that enable them to include your married longer, in good robustness, and fuller live. Since 1923, Lilly have be the industry editorial...
www.OSIR.org.in (Free subscription) | 25/11/2008
Nov. 4 (Bloomberg) — The following companies are having unusual price changes in U.S. trading today. Stock symbols are in parentheses, and share prices are as of 12:15 p.m. in New York. Amylin Pharmaceuticals Inc. (AMLN US) retreated 21 percent to Source: www.bloomberg.com UPDATE 1-Genzyme, Osiris to develop stem cell products - ReutersNov 4 [...]
The Street (Free subscription) | 24/11/2008
The regulatory agency is alerting diabetes-drug makers, like Amylin, of new heart-safety data standards.
